Allison Ross Eckard1, Heather Y Hughes1,2, Nancy L Hagood1, Mary Ann O'Riordan3, Danielle Labbato3, Julia C Kosco3, Sarah E Scott3, Grace A McComsey3,4. 1. Department of Pediatrics and Medicine, Medical University of South Carolina, Charleston, SC. 2. Department of Medicine, Ralph H. Johnson VA Medical Center, Charleston, SC. 3. Department of Pediatrics, University Hospitals Cleveland Medical Center, Cleveland, OH; and. 4. Department of Pediatrics and Medicine, Case Western Reserve University School of Medicine, Cleveland, OH.
Abstract
BACKGROUND: Fecal calprotectin (FC), a biomarker of gastrointestinal (GI) inflammation, is used in the diagnosis and management of inflammatory bowel disease. HIV infection severely damages gut-associated lymphoid and epithelial tissues leading to GI inflammation that drives systemic inflammation and increases subsequent risk of comorbidities. For the first time, we compared FC concentrations by HIV and antiretroviral therapy (ART) status and determined the relationship to systemic inflammation. METHODS: People with and without HIV were enrolled and underwent a comprehensive clinical and laboratory assessment. Stool samples were collected, and FC was measured by enzyme-linked immunosorbent assay ELISA. Plasma biomarkers of inflammation were also measured. RESULTS: One hundred one participants with HIV (83 ART-treated and 18 ART-naive) and 89 uninfected controls were enrolled. There were no significant differences between ART-naive and ART-treated participants, but both HIV groups had significantly higher FC concentrations than controls when FC was considered as a continuous variable or by cut-offs used in inflammatory bowel disease. The highest median and largest proportion of participants with FC >100 µg/g were seen in ART-naive, followed by ART-treated and then controls. Among HIV participants, FC concentrations were positively associated with high-sensitivity C-reactive protein, soluble tumor necrosis factor receptor II, and soluble vascular cellular adhesion molecule and inversely associated with CD4 counts. CONCLUSIONS: FC concentrations are elevated in HIV regardless of ART status. ART and immune reconstitution seem to reduce FC but not to concentrations seen in uninfected controls. Our results suggest a role for FC as a noninvasive surrogate measurement of GI inflammation and associated systemic inflammation in HIV.
BACKGROUND: Fecal calprotectin (FC), a biomarker of gastrointestinal (GI) inflammation, is used in the diagnosis and management of inflammatory bowel disease. HIV infection severely damages gut-associated lymphoid and epithelial tissues leading to GI inflammation that drives systemic inflammation and increases subsequent risk of comorbidities. For the first time, we compared FC concentrations by HIV and antiretroviral therapy (ART) status and determined the relationship to systemic inflammation. METHODS: People with and without HIV were enrolled and underwent a comprehensive clinical and laboratory assessment. Stool samples were collected, and FC was measured by enzyme-linked immunosorbent assay ELISA. Plasma biomarkers of inflammation were also measured. RESULTS: One hundred one participants with HIV (83 ART-treated and 18 ART-naive) and 89 uninfected controls were enrolled. There were no significant differences between ART-naive and ART-treated participants, but both HIV groups had significantly higher FC concentrations than controls when FC was considered as a continuous variable or by cut-offs used in inflammatory bowel disease. The highest median and largest proportion of participants with FC >100 µg/g were seen in ART-naive, followed by ART-treated and then controls. Among HIV participants, FC concentrations were positively associated with high-sensitivity C-reactive protein, soluble tumor necrosis factor receptor II, and soluble vascular cellular adhesion molecule and inversely associated with CD4 counts. CONCLUSIONS: FC concentrations are elevated in HIV regardless of ART status. ART and immune reconstitution seem to reduce FC but not to concentrations seen in uninfected controls. Our results suggest a role for FC as a noninvasive surrogate measurement of GI inflammation and associated systemic inflammation in HIV.
Authors: Timothy W Schacker; Jason M Brenchley; Gregory J Beilman; Cavan Reilly; Stefan E Pambuccian; Jodie Taylor; David Skarda; Matthew Larson; Daniel C Douek; Ashley T Haase Journal: Clin Vaccine Immunol Date: 2006-05
Authors: Wing Yan Mak; Anthony Buisson; Michael J Andersen; Donald Lei; Joel Pekow; Russell D Cohen; Stacy A Kahn; Bruno Pereira; David T Rubin Journal: Dig Dis Sci Date: 2018-02-22 Impact factor: 3.199
Authors: Thomas E Kehl-Fie; Seth Chitayat; M Indriati Hood; Steven Damo; Nicole Restrepo; Carlos Garcia; Kim A Munro; Walter J Chazin; Eric P Skaar Journal: Cell Host Microbe Date: 2011-08-18 Impact factor: 21.023
Authors: Thomas Vogl; Klaus Tenbrock; Stephan Ludwig; Nadja Leukert; Christina Ehrhardt; Marieke A D van Zoelen; Wolfgang Nacken; Dirk Foell; Tom van der Poll; Clemens Sorg; Johannes Roth Journal: Nat Med Date: 2007-09-02 Impact factor: 53.440
Authors: Alain M Schoepfer; Christoph Beglinger; Alex Straumann; Michael Trummler; Pietro Renzulli; Frank Seibold Journal: Inflamm Bowel Dis Date: 2009-05-21 Impact factor: 5.325
Authors: Pablo Villoslada-Blanco; Patricia Pérez-Matute; María Íñiguez; Emma Recio-Fernández; Pilar Blanco-Navarrete; Luis Metola; Valvanera Ibarra; Jorge Alba; María de Toro; José A Oteo Journal: Infect Dis Ther Date: 2022-05-26